Predictive biomarkers in colorectal cancer: Usage, validation, and design in clinical trials

Qian D Shi, Sumithra J Mandrekar, Daniel J. Sargent

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

As cancer treatment development has shifted its attention to targeted therapies, it is becoming increasingly important to provide tools for selecting the right treatment for an individual patient to achieve optimal clinical benefit. Biomarkers, identified and studied in the process of understanding the nature of the disease at the molecular pathogenesis level, have been increasingly recognized as a critical aspect in more accurate diagnosis, prognosis assessment, and therapeutic targeting. Predictive biomarkers, which can aid treatment decisions, require extensive data for validation. In this article, we discuss the definition, clinical usages, and more extensively the clinical trial designs for the validation of predictive biomarkers. Predictive biomarker validation methods can be broadly grouped into retrospective and prospective designs. Retrospective validation utilizes data from previously conducted prospective randomized controlled trials. Prospective designs include enrichment designs, treatment-by-marker interaction designs, marker-based strategy designs, and adaptive designs. We discuss each design with examples and provide comparisons of the advantages and disadvantages among the different designs. We conclude that the combination of scientific, clinical, statistical, ethical, and practical considerations provides guidance for the choice of the clinical trial design for validation of each proposed predictive biomarker.

Original languageEnglish (US)
Pages (from-to)356-362
Number of pages7
JournalScandinavian Journal of Gastroenterology
Volume47
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Colorectal Neoplasms
Biomarkers
Clinical Trials
Therapeutics
Decision Support Techniques
Randomized Controlled Trials
Neoplasms

Keywords

  • clinical trial design
  • clinical utility
  • predictive biomarker
  • validation

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Predictive biomarkers in colorectal cancer : Usage, validation, and design in clinical trials. / Shi, Qian D; Mandrekar, Sumithra J; Sargent, Daniel J.

In: Scandinavian Journal of Gastroenterology, Vol. 47, No. 3, 03.2012, p. 356-362.

Research output: Contribution to journalArticle

@article{dc99fccf6c82487fa7071aeff2be380b,
title = "Predictive biomarkers in colorectal cancer: Usage, validation, and design in clinical trials",
abstract = "As cancer treatment development has shifted its attention to targeted therapies, it is becoming increasingly important to provide tools for selecting the right treatment for an individual patient to achieve optimal clinical benefit. Biomarkers, identified and studied in the process of understanding the nature of the disease at the molecular pathogenesis level, have been increasingly recognized as a critical aspect in more accurate diagnosis, prognosis assessment, and therapeutic targeting. Predictive biomarkers, which can aid treatment decisions, require extensive data for validation. In this article, we discuss the definition, clinical usages, and more extensively the clinical trial designs for the validation of predictive biomarkers. Predictive biomarker validation methods can be broadly grouped into retrospective and prospective designs. Retrospective validation utilizes data from previously conducted prospective randomized controlled trials. Prospective designs include enrichment designs, treatment-by-marker interaction designs, marker-based strategy designs, and adaptive designs. We discuss each design with examples and provide comparisons of the advantages and disadvantages among the different designs. We conclude that the combination of scientific, clinical, statistical, ethical, and practical considerations provides guidance for the choice of the clinical trial design for validation of each proposed predictive biomarker.",
keywords = "clinical trial design, clinical utility, predictive biomarker, validation",
author = "Shi, {Qian D} and Mandrekar, {Sumithra J} and Sargent, {Daniel J.}",
year = "2012",
month = "3",
doi = "10.3109/00365521.2012.640836",
language = "English (US)",
volume = "47",
pages = "356--362",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Predictive biomarkers in colorectal cancer

T2 - Usage, validation, and design in clinical trials

AU - Shi, Qian D

AU - Mandrekar, Sumithra J

AU - Sargent, Daniel J.

PY - 2012/3

Y1 - 2012/3

N2 - As cancer treatment development has shifted its attention to targeted therapies, it is becoming increasingly important to provide tools for selecting the right treatment for an individual patient to achieve optimal clinical benefit. Biomarkers, identified and studied in the process of understanding the nature of the disease at the molecular pathogenesis level, have been increasingly recognized as a critical aspect in more accurate diagnosis, prognosis assessment, and therapeutic targeting. Predictive biomarkers, which can aid treatment decisions, require extensive data for validation. In this article, we discuss the definition, clinical usages, and more extensively the clinical trial designs for the validation of predictive biomarkers. Predictive biomarker validation methods can be broadly grouped into retrospective and prospective designs. Retrospective validation utilizes data from previously conducted prospective randomized controlled trials. Prospective designs include enrichment designs, treatment-by-marker interaction designs, marker-based strategy designs, and adaptive designs. We discuss each design with examples and provide comparisons of the advantages and disadvantages among the different designs. We conclude that the combination of scientific, clinical, statistical, ethical, and practical considerations provides guidance for the choice of the clinical trial design for validation of each proposed predictive biomarker.

AB - As cancer treatment development has shifted its attention to targeted therapies, it is becoming increasingly important to provide tools for selecting the right treatment for an individual patient to achieve optimal clinical benefit. Biomarkers, identified and studied in the process of understanding the nature of the disease at the molecular pathogenesis level, have been increasingly recognized as a critical aspect in more accurate diagnosis, prognosis assessment, and therapeutic targeting. Predictive biomarkers, which can aid treatment decisions, require extensive data for validation. In this article, we discuss the definition, clinical usages, and more extensively the clinical trial designs for the validation of predictive biomarkers. Predictive biomarker validation methods can be broadly grouped into retrospective and prospective designs. Retrospective validation utilizes data from previously conducted prospective randomized controlled trials. Prospective designs include enrichment designs, treatment-by-marker interaction designs, marker-based strategy designs, and adaptive designs. We discuss each design with examples and provide comparisons of the advantages and disadvantages among the different designs. We conclude that the combination of scientific, clinical, statistical, ethical, and practical considerations provides guidance for the choice of the clinical trial design for validation of each proposed predictive biomarker.

KW - clinical trial design

KW - clinical utility

KW - predictive biomarker

KW - validation

UR - http://www.scopus.com/inward/record.url?scp=84857144592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857144592&partnerID=8YFLogxK

U2 - 10.3109/00365521.2012.640836

DO - 10.3109/00365521.2012.640836

M3 - Article

C2 - 22181041

AN - SCOPUS:84857144592

VL - 47

SP - 356

EP - 362

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 3

ER -